(SNN) Smith & Nephew SNATS - Ratings and Ratios
Knee Implants, Hip Implants, Sports Medicine, Wound Therapy, Biologics
SNN EPS (Earnings per Share)
SNN Revenue
Description: SNN Smith & Nephew SNATS October 31, 2025
Smith & Nephew plc (NYSE:SNN) develops, manufactures, markets, and sells medical-device products and related services from its headquarters in Watford, UK, serving providers in the United Kingdom, the United States, and other international markets.
The business is organized into three operating segments: Orthopaedics; Sports Medicine & ENT; and Advanced Wound Management. Orthopaedics covers knee and hip implants (including revision and trauma solutions); Sports Medicine & ENT supplies minimally invasive joint-repair instruments, arthroscopic visualization equipment, and ear-nose-throat devices; Advanced Wound Management offers bioactive dressings, negative-pressure therapy, and regenerative-medicine products such as skin and bone grafts.
According to the FY 2023 results released in February 2024, the company generated approximately $5.1 billion in revenue, with a 6 % year-over-year increase driven primarily by orthopaedic sales in the United States. The operating margin expanded to 13.2 % (up from 11.8 % in FY 2022) as a result of higher implant pricing and cost-discipline in wound-care manufacturing. R&D spending remained steady at roughly 8 % of revenue, reflecting continued investment in next-generation arthroscopy platforms and bioactive wound technologies.
Key macro-economic drivers for SNN include the aging global population (the 65 + demographic is projected to grow 15 % by 2030, boosting demand for joint replacement), the post-COVID elective-surgery backlog (estimated to add $3-4 billion of deferred procedures in the U.S. over the next two years), and tightening reimbursement policies in major markets, which can pressure pricing but also incentivize higher-value, technology-enabled solutions.
Consider checking ValueRay for a deeper quantitative assessment of SNN’s valuation and risk profile.
SNN Stock Overview
| Market Cap in USD | 15,606m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1999-11-16 |
SNN Stock Ratings
| Growth Rating | 62.9% |
| Fundamental | 70.9% |
| Dividend Rating | 32.7% |
| Return 12m vs S&P 500 | 25.1% |
| Analyst Rating | 3.75 of 5 |
SNN Dividends
| Dividend Yield 12m | 2.06% |
| Yield on Cost 5y | 2.34% |
| Annual Growth 5y | 0.00% |
| Payout Consistency | 95.3% |
| Payout Ratio | 115.5% |
SNN Growth Ratios
| Growth Correlation 3m | -21.7% |
| Growth Correlation 12m | 93.4% |
| Growth Correlation 5y | -36.3% |
| CAGR 5y | 18.88% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.57 |
| CAGR/Mean DD 3y (Pain Ratio) | 1.74 |
| Sharpe Ratio 12m | 1.33 |
| Alpha | 36.27 |
| Beta | 0.673 |
| Volatility | 24.44% |
| Current Volume | 707.1k |
| Average Volume 20d | 496k |
| Stop Loss | 35.9 (-3%) |
| Signal | 0.97 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (814.6m TTM) > 0 and > 6% of Revenue (6% = 612.7m TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 5.42pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 30.20% (prev 21.13%; Δ 9.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.14 (>3.0%) and CFO 1.51b > Net Income 814.6m (YES >=105%, WARN >=100%) |
| Net Debt (2.78b) to EBITDA (2.22b) ratio: 1.25 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.00 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (439.9m) change vs 12m ago -49.60% (target <= -2.0% for YES) |
| Gross Margin 69.95% (prev 70.14%; Δ -0.19pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 98.80% (prev 83.34%; Δ 15.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.98 (EBITDA TTM 2.22b / Interest Expense TTM 254.8m) >= 6 (WARN >= 3) |
Altman Z'' 5.29
| (A) 0.29 = (Total Current Assets 4.62b - Total Current Liabilities 1.54b) / Total Assets 10.68b |
| (B) 0.48 = Retained Earnings (Balance) 5.12b / Total Assets 10.68b |
| (C) 0.12 = EBIT TTM 1.27b / Avg Total Assets 10.33b |
| (D) 0.96 = Book Value of Equity 4.96b / Total Liabilities 5.15b |
| Total Rating: 5.29 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 70.87
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 4.89% = 2.44 |
| 3. FCF Margin 8.80% = 2.20 |
| 4. Debt/Equity 0.62 = 2.31 |
| 5. Debt/Ebitda 1.25 = 1.39 |
| 6. ROIC - WACC (= 4.61)% = 5.77 |
| 7. RoE 15.37% = 1.28 |
| 8. Rev. Trend 47.93% = 3.59 |
| 9. EPS Trend -2.19% = -0.11 |
What is the price of SNN shares?
Over the past week, the price has changed by +1.31%, over one month by +3.09%, over three months by +21.23% and over the past year by +50.10%.
Is Smith & Nephew SNATS a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SNN is around 35.56 USD . This means that SNN is currently overvalued and has a potential downside of -3.94%.
Is SNN a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SNN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 37.4 | 1.1% |
| Analysts Target Price | 37.4 | 1.1% |
| ValueRay Target Price | 39.2 | 6% |
SNN Fundamental Data Overview November 04, 2025
P/E Trailing = 32.875
P/E Forward = 13.6054
P/S = 2.6255
P/B = 2.802
P/EG = 0.896
Beta = 0.673
Revenue TTM = 10.21b USD
EBIT TTM = 1.27b USD
EBITDA TTM = 2.22b USD
Long Term Debt = 3.15b USD (from longTermDebt, last quarter)
Short Term Debt = 156.9m USD (from shortTermDebt, last quarter)
Debt = 3.45b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.78b USD (from netDebt column, last quarter)
Enterprise Value = 18.38b USD (15.61b + Debt 3.45b - CCE 675.4m)
Interest Coverage Ratio = 4.98 (Ebit TTM 1.27b / Interest Expense TTM 254.8m)
FCF Yield = 4.89% (FCF TTM 898.3m / Enterprise Value 18.38b)
FCF Margin = 8.80% (FCF TTM 898.3m / Revenue TTM 10.21b)
Net Margin = 7.98% (Net Income TTM 814.6m / Revenue TTM 10.21b)
Gross Margin = 69.95% ((Revenue TTM 10.21b - Cost of Revenue TTM 3.07b) / Revenue TTM)
Gross Margin QoQ = 70.62% (prev 69.46%)
Tobins Q-Ratio = 1.72 (Enterprise Value 18.38b / Total Assets 10.68b)
Interest Expense / Debt = 2.37% (Interest Expense 81.7m / Debt 3.45b)
Taxrate = 19.06% (69.6m / 365.3m)
NOPAT = 1.03b (EBIT 1.27b * (1 - 19.06%))
Current Ratio = 3.00 (Total Current Assets 4.62b / Total Current Liabilities 1.54b)
Debt / Equity = 0.62 (Debt 3.45b / totalStockholderEquity, last quarter 5.53b)
Debt / EBITDA = 1.25 (Net Debt 2.78b / EBITDA 2.22b)
Debt / FCF = 3.09 (Net Debt 2.78b / FCF TTM 898.3m)
Total Stockholder Equity = 5.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.63% (Net Income 814.6m / Total Assets 10.68b)
RoE = 15.37% (Net Income TTM 814.6m / Total Stockholder Equity 5.30b)
RoCE = 15.01% (EBIT 1.27b / Capital Employed (Equity 5.30b + L.T.Debt 3.15b))
RoIC = 11.92% (NOPAT 1.03b / Invested Capital 8.62b)
WACC = 7.31% (E(15.61b)/V(19.06b) * Re(8.50%) + D(3.45b)/V(19.06b) * Rd(2.37%) * (1-Tc(0.19)))
Discount Rate = 8.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -29.01%
[DCF Debug] Terminal Value 77.68% ; FCFE base≈658.4m ; Y1≈705.3m ; Y5≈858.7m
Fair Price DCF = 32.48 (DCF Value 13.77b / Shares Outstanding 423.8m; 5y FCF grow 7.97% → 3.0% )
EPS Correlation: -2.19 | EPS CAGR: -66.95% | SUE: 0.0 | # QB: 0
Revenue Correlation: 47.93 | Revenue CAGR: 35.34% | SUE: N/A | # QB: 0
Additional Sources for SNN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle